OM:BIOG B

Stock Analysis Report

Executive Summary

BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide.

Snowflake

Fundamentals

Flawless balance sheet with proven track record and pays a dividend.


Similar Companies

Share Price & News

How has BioGaia's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

2.1%

BIOG B

2.3%

SE Biotechs

2.2%

SE Market


1 Year Return

9.9%

BIOG B

-16.5%

SE Biotechs

16.0%

SE Market

Return vs Industry: BIOG B exceeded the Swedish Biotechs industry which returned -16.5% over the past year.

Return vs Market: BIOG B underperformed the Swedish Market which returned 16% over the past year.


Shareholder returns

BIOG BIndustryMarket
7 Day2.1%2.3%2.2%
30 Day-9.5%-2.0%2.7%
90 Day-3.7%-14.6%4.2%
1 Year12.4%9.9%-16.1%-16.5%21.0%16.0%
3 Year49.3%39.8%29.7%19.8%34.5%14.2%
5 Year130.7%106.9%51.2%53.3%61.7%27.1%

Price Volatility Vs. Market

How volatile is BioGaia's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BioGaia undervalued compared to its fair value and its price relative to the market?

32.94x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: BIOG B (SEK390) is trading above our estimate of fair value (SEK243.96)

Significantly Below Fair Value: BIOG B is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: BIOG B is good value based on its PE Ratio (32.9x) compared to the Biotechs industry average (33.1x).

PE vs Market: BIOG B is poor value based on its PE Ratio (32.9x) compared to the Swedish market (16.9x).


Price to Earnings Growth Ratio

PEG Ratio: BIOG B is poor value based on its PEG Ratio (2.3x)


Price to Book Ratio

PB vs Industry: BIOG B is overvalued based on its PB Ratio (16.2x) compared to the SE Biotechs industry average (3.7x).


Next Steps

Future Growth

How is BioGaia forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

14.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BIOG B's forecast earnings growth (14.6% per year) is above the savings rate (0.4%).

Earnings vs Market: BIOG B's earnings (14.6% per year) are forecast to grow faster than the Swedish market (8.8% per year).

High Growth Earnings: BIOG B's earnings are forecast to grow, but not significantly.

Revenue vs Market: BIOG B's revenue (12.7% per year) is forecast to grow faster than the Swedish market (4.5% per year).

High Growth Revenue: BIOG B's revenue (12.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BIOG B's Return on Equity is forecast to be very high in 3 years time (47.7%).


Next Steps

Past Performance

How has BioGaia performed over the past 5 years?

11.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: BIOG B's earnings have grown by 11.7% per year over the past 5 years.

Accelerating Growth: BIOG B's earnings growth over the past year (4.3%) is below its 5-year average (11.7% per year).

Earnings vs Industry: BIOG B earnings growth over the past year (4.3%) underperformed the Biotechs industry 29.4%.


Return on Equity

High ROE: BIOG B's Return on Equity (49.2%) is considered outstanding.


Return on Assets

ROA vs Industry: BIOG B has a higher Return on Assets than the Biotechs industry average last year.


Return on Capital Employed

ROCE Improving: BIOG B has improved its Return on Capital Employed over the past 3 years.


Next Steps

Financial Health

How is BioGaia's financial position?


Financial Position Analysis

Short Term Liabilities: BIOG B's short term assets (SEK397.9M) exceeds its short term liabilities (SEK148.0M)

Long Term Liabilities: BIOG B's short term assets (397.9M) exceeds its long term liabilities (32.0M)


Debt to Equity History and Analysis

Debt Level: BIOG B is debt free.

Reducing Debt: BIOG B has not had any debt for past 5 years.

Debt Coverage: BIOG B has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: BIOG B has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: BIOG B has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if BIOG B's debt is covered by short term assets.


Next Steps

Dividend

What is BioGaia's current dividend yield, its reliability and sustainability?

2.56%

Current Dividend Yield


Dividend Yield vs Market

company2.6%marketbottom25%1.8%markettop25%4.7%industryaverage1.2%forecastin3Years2.8%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: BIOG B's dividend (2.56%) is higher than the bottom 25% of dividend payers in the Swedish market (1.81%).

High Dividend: BIOG B's dividend (2.56%) is low compared to the top 25% of dividend payers in the Swedish market (4.71%).

Stable Dividend: BIOG B's dividend payments have been volatile in the past 10 years.

Growing Dividend: BIOG B's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (34.2%), BIOG B's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: BIOG B's dividends in 3 years are forecast to be covered by earnings (80.8% payout ratio).


Next Steps

Management

What is the CEO of BioGaia's salary, the management and board of directors tenure and is there insider trading?

5.6yrs

Average management tenure


CEO

Isabelle Valerie Ducellier (50yo)

0yrs

Tenure

kr3,462,839

Compensation

Ms. Isabelle Valerie Ghislaine Ducellier serves as the Chief Executive Officer of BioGaia AB. Ms. Ducellier has been Partner and Consultant at Anian Ab since 2016. Ms. Ducellier has been Visiting Lecturer  ...


CEO Compensation Analysis

Compensation vs. Market: Isabelle Valerie's total compensation ($USD359.59K) is below average for companies of similar size in the Swedish market ($USD602.12K).

Compensation vs Earnings: Insufficient data to compare Isabelle Valerie's compensation with company performance.


Management Age and Tenure

5.6yrs

Average Tenure

53yo

Average Age

Experienced Management: BIOG B's management team is seasoned and experienced (5.6 years average tenure).


Board Age and Tenure

4.4yrs

Average Tenure

69yo

Average Age

Experienced Board: BIOG B's board of directors are considered experienced (4.4 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Buykr99,59012 Jun 19
Isabelle Valerie Ducellier
EntityIndividual
Role
Chief Executive Officer
Chief Executive Officer
Shares230
Max Pricekr433.00
Sellkr1,386,00021 May 19
Margareta Hagman
EntityIndividual
Role
Chief Financial Officer
Executive Vice President of Accounting
Shares3,000
Max Pricekr462.00
Buykr18,77921 Mar 19
Kristina Borg
EntityIndividual
Shares40
Max Pricekr469.48
Buykr86,45001 Mar 19
Peter Rothschild
EntityIndividual
Role
Chairman of the Board
Founder & Chairman
Shares200
Max Pricekr432.25
Sellkr31,786,97626 Nov 18
Annwall & Rothschild Investments AB
EntityCompany
Shares92,404
Max Pricekr344.00
Sellkr1,671,84319 Nov 18
Peter Rothschild
EntityIndividual
Role
Chairman of the Board
Founder & Chairman
Shares4,700
Max Pricekr355.71

Ownership Breakdown


Management Team

  • Peter Rothschild (69yo)

    Founder & Chairman

    • Tenure: 1.5yrs
    • Compensation: kr7.16m
  • Bo Möllstam (67yo)

    Acting Head of Research

    • Tenure: 0.8yrs
  • Margareta Hagman (53yo)

    Executive Vice President of Accounting

    • Tenure: 9.5yrs
  • Urban Strindlöv (55yo)

    Executive VP & Sales Director

    • Tenure: 9.8yrs
  • Staffan Strömberg (52yo)

    Vice President of Development & Regulatory Affairs

    • Tenure: 0yrs
  • Isabelle Valerie Ducellier (50yo)

    Chief Executive Officer

    • Tenure: 0yrs
    • Compensation: kr3.46m
  • Katayoun Welin-Berger (51yo)

    Vice President of Operations

    • Tenure: 0yrs
  • Ulrika Köhler (53yo)

    Vice President of Marketing & Product Development

    • Tenure: 0yrs
  • Angelika Kjelldorff

    Vice President of Human Resources

    • Tenure: 0.8yrs
  • Marika Isberg (46yo)

    VP & General Counsel

    • Tenure: 1.7yrs

Board Members

  • Peter Rothschild (69yo)

    Founder & Chairman

    • Tenure: 1.5yrs
    • Compensation: kr7.16m
  • David E. Dangoor (70yo)

    Deputy Chairman

    • Tenure: 1.5yrs
    • Compensation: kr400.00k
  • Inger Holmström (71yo)

    Director

    • Tenure: 12.8yrs
    • Compensation: kr200.00k
  • Peter Elving (71yo)

    Director

    • Tenure: 1.5yrs
    • Compensation: kr200.00k
  • Brit Stakston (58yo)

    Director

    • Tenure: 5.8yrs
    • Compensation: kr200.00k
  • Anthon Jahreskog (39yo)

    Director

    • Tenure: 4.4yrs
    • Compensation: kr200.00k
  • Ewa Björling (58yo)

    Director

    • Tenure: 4.4yrs
    • Compensation: kr200.00k

Company Information

BioGaia AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BioGaia AB (publ)
  • Ticker: BIOG B
  • Exchange: OM
  • Founded: 1990
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr6.761b
  • Shares outstanding: 17.34m
  • Website: https://www.biogaia.com

Number of Employees


Location

  • BioGaia AB (publ)
  • Kungsbroplan 3
  • Stockholm
  • Stockholm County
  • 112 27
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BIOG BOM (OMX Nordic Exchange Stockholm)YesClass B SharesSESEKMay 1998
BGLDB (Deutsche Boerse AG)YesClass B SharesDEEURMay 1998
0GTNLSE (London Stock Exchange)YesClass B SharesGBSEKMay 1998
BGAI.FOTCPK (Pink Sheets LLC)YesClass B SharesUSUSDMay 1998
BIOGBsBATS-CHIXE (BATS 'Chi-X Europe')YesClass B SharesGBSEKMay 1998
BIOG.YOTCPK (Pink Sheets LLC)UNSPONSORED ADRUSUSDApr 2013

Biography

BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide. It operates in Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/22 20:42
End of Day Share Price2019/10/22 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.